All In MedTech

Device Trial Radar · NCT06717451

PS230005 Control-IQ 1.5 Post-Approval Study

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

144

Actual

Start

Jan 30, 2025

Primary completion

Aug 10, 2026

Study completion Aug 10, 2026

Sponsor

Lead sponsor
Tandem Diabetes Care, Inc.Public (TNDM)
Sponsor type
Industry
Collaborators
University of California, San Diego
First posted
Dec 5, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 2 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to \<6 years old. Participants will use Control-IQ technology v1.5 for 12 months in the real-world setting.

Conditions

  • Type 1 Diabetes

Interventions

  • Control-IQ Technology v1.5Device

    Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ technology v1.5. Every month participants will receive a survey to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment. Participants will also complete surveys related to patient reported outcomes at baseline, 6 months, and 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rates of Severe Hypoglycemia (SH)Time frame: 12 months
  2. Incidence Rates of Diabetic Ketoacidosis (DKA)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tandem Diabetes Care

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.